Abstract
Allergen immunotherapy has been in use for nearly 100 yr and has become an important method of reducing allergic symptoms in select patients with allergic rhinitis, asthma, and insect venom hypersensitivity. Unfortunately, immunotherapy has been associated with anaphylaxis and death. Although the relative risk of severe reactions to immunotherapy is low, the number of such reactions has increased since the introduction of standardized and more potent extracts. There are a number of risk factors associated with such severe anaphylactic reactions. Such risk factors include errors in dosage, failure to reduce the dosage after a longer than scheduled interval, administration of the wrong extract, inadvertent intravenous administration, failure to postpone injection because of infection or asthma exacerbation, failure to observe patients for appropriate length of time, failure to adhere to guidelines for established contraindications, concurrent use of β-adrenergic blocking agents, uses of mixtures of allergens, immunotherapy during the active allergy season, and types of allergens. In this review, we focus on these and other risk factors in attempts to reduce the risk of anaphylaxis following allergen immunotherapy.
Similar content being viewed by others
References
Lamson, R. W. (1924), JAMA 82, 1090–1098.
Lamson, R. W. (1929) JAMA 93, 1775–1778.
Lockey, R. F., Nicoara-Kasti, G. L., Theodoropoulos, D. S., and Bukantz, S. C. (2001), Ann. Allergy Asthma Immunol. 87(1 Suppl 1), 47–55.
Lockey, R. F., Benedict, L. M., Turkeltaub, P. C., and Bukantz, S. C. (1987), J. Allergy Clin. Immunol. 79, 660–677.
Reid, M. J., Lockey, R. F., Turkeltaub P. C., and Platts-Mills, T. A. (1993), J. Allergy Clin. Immunol. 92, 6–15.
Reid, M. J., Lockey, R. F., Turkeltaub, P., Platts-Mills, T. A. E., and Lehrer, S. B. (1992), J. Allergy Clin. Immunol. 89, 350.
Kordash, T., and Miller, J. (1997), J. Allergy Clin. Immunol. 99, S67.
American College of Allergy Asthma and Immunology. Fact Sheet: Efficacy and Safety of Immunotherapy. http://allergy.mcg.edu/patients/ factsheet.html.
Terr A. I., and Bloch D. A. (1996), Ann. Allergy Asthma Immunol. 76, 273–281.
Committee on Safety of Medicines. (1986), BMJ 293, 948.
Lüderitz-Püchel, U., May, S., and Haustein, D. (1996), Munch. Med. Wochenschr. 138, 129–132.
Executive Committee AAAI. (1990), J. Allergy Clin. Immunol. 85, 526–527.
Toubi, E., Kessel, A., Blant, A., and Golan, T. D. (1999), Allergy 54, 617–620.
Mellerup, M. T., Hahn, G. W., Poulsen, L. K., and Malling, H.-J. (2000), Clin. Exp. Allergy 30, 1423–1429.
Nettis, E., Giordano, D., Pannofino, A., Ferrannini, A., and Tursi, A. (2002), Clin. Exp. Allergy 32, 1745–1749.
Tabar, A. I., García, B. E., Rodríguez, A., Olaguibel, J. M., Muro, M. D., and Quirce, S. (1993), Allergy 48, 450–453.
Moreno, C., Cuesta-Herranz, J., Fernández-Távora, L., and Alvarez-Cuesta, E. (2004), Clin. Exp. Allergy 34, 527–531.
Gastaminza, G., Algorta, J., Audicana, M., Etxenaugusia, M., Fernández, E., and Muñoz, D. (2003), Clin. Exp. Allergy 33, 470–474.
Mosbech, H., and Müller, U. (2000), Allergy 55, 1005–1010.
Bousquet, J., Hejjaoui, A., Dhivert, H., Clauzel, A. M., and Michel, F. B. (1989), J. Allergy Clin. Immunol. 83, 797–802.
Malling, H.-J., and Weeke, B., eds. (1993), Allergy 48(14 Suppl), 7–35.
Thoracic Society of Australia and New Zealand and the Australasian Society of Clinical Immunology and Allergy. (1997), Med. J. Aust. 167, 540–544.
Li, J. T., Lockey, R. F., Bernstein, I. L., Portnoy, J. M., Nicklas, R. A. (2003), Ann. Allergy Asthma Immunol. 90, 1–40.
Lockey, R. F., Turkeltaub, P. C., Olive, E. S., Hubbard, J. M., Baird-Warren, I. A., and Bukantz, S. C. (1990), J. Allergy Clin. Immunol. 86, 775–780.
Greenberg, M. A., Kaufman, C. R., Gonzalez, G. E., Rosenblatt, C. D., Smith, L. J., and Summers, R. J. J. (1986), Allergy Clin. Immunol. 77, 865–870.
Businco, L., Zannino, L., Cantani, A., Corrias, A., Fiocchi, A., and La Rosa, M. (1995), Pediatr. Allergy Immunol. 6, 44–47.
Lin, M. S., Tanner, E., Lynn, J., and Friday, G. A., Jr. (1993), Ann. Allergy 71, 557–562.
Müller, U., and Mosbech, H. (1993), Allergy 48(14 Suppl), 36–46.
Bousquet, J., Lockey, R. F., and Malling, H.-J. (1998), Allergy 53(Suppl 44), 1–42.
Hepner, M. J., Ownby, D. R., Anderson, J. A., Rowe, M. S., Sears-Ewald, D., and Brown, E. B. (1990), J. Allergy Clin. Immunol. 86, 407–411.
Bousquet, J., Lockey, R., Malling, H.-J., and The WHO panel members. (1998), J. Allergy Clin. Immunol. 102, 558–562.
Van Arsdel, P. P., Jr., and Sherman, W. B. (1957), J. Allergy 28, 251–261.
Winther, L., Malling, H.-J., and Mosbech, H. (2000), Allergy 55, 827–835.
Birnbaum, J., Ramadour, M., Magnan, A., and Vervloet, D. (2003), Clin. Exp. Allergy 33, 58–64.
Practice parameters for allergen immunotherapy. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. (1996), J. Allergy Clin. Immunol. 98, 1001–1011.
Antonicelli, L., Bilò, M. B., and Bonifazi, F. (2002), Curr. Opin. Allergy Clin. Immunol. 2, 341–346.
Brown, S. G., and Heddle, R. J. (2003), Curr. Opin. Allergy Clin. Immunol. 3, 511–516.
Brown, S. G., Franks, R. W., Baldo, B. A., and Heddle, R. J. (2003), J. Allergy Clin. Immunol. 111, 187–192.
Brown, S. G. A., Wiese, M. D., Blackman, K. E., and Heddle, R. J. (2003), Lancet 361, 1001–1006.
Harvey, P., Sperber, S., Kette, F., Heddle, R. J., and Roberts-Thomson, P. J. (1984), Med. J. Aust. 140, 209–211.
Abramson, M. J., Puy, R. M., and Weiner, J. M. (2003), Cochrane Database Syst. Rev. 2, 2004.
Wilson, D. R., Torres Lima, M., and Durham, S. R. (2003), Cochrane Database Syst. Rev. 2, 2004.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Borchers, A.T., Keen, C.L. & Gershwin, M.E. Fatalities following allergen immunotherapy. Clinic Rev Allerg Immunol 27, 147–158 (2004). https://doi.org/10.1385/CRIAI:27:2:147
Issue Date:
DOI: https://doi.org/10.1385/CRIAI:27:2:147